Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Open Access
- 7 November 2008
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 24 (2) , 682-685
Abstract
Background. Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA). Most cases of TMA are reported secondary to bevacizumab. It was shown recently that sunitinib, a small molecule inhibiting several tyrosine kinase receptors, including VEGF receptors, can also induce proteinuria, hypertension and biological features of TMA. Case. A 44-year-old woman with a history of malignant skin hidradenoma was started on sunitinib for refractory disease. She developed hypertension after 2 weeks and low-grade proteinuria after 4 weeks. Renal function remained normal, and biological signs of TMA were absent. A renal biopsy was performed 6 months later as proteinuria persisted, demonstrating typical features of TMA. The patient was given irbesartan, and sunitinib was continued for 3 months after diagnosis. Over this period, blood pressure and renal function remained stable and proteinuria became undetectable. Conclusion. We report on the first case of histologically documented TMA secondary to sunitinib and provide detailed description of renal histological involvement. This suggests that all anti-VEGF drugs may share a common risk for developing renal adverse events, including TMA. Our case highlights the possible discrepancy between mild clinical manifestation on one hand and severe TMA features on renal biopsy on the other hand and pleads for large indication of renal biopsy in this setting. The renin–angiotensin system blockers may be considered in patients with mild clinical manifestations and in the absence of therapeutic alternative to anti-VEGF drugs.Keywords
This publication has 15 references indexed in Scilit:
- The Case ∣ Progressive hypertension and proteinuria on anti-angiogenic therapyKidney International, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and SorafenibJNCI: Journal of the National Cancer Institute, 2008
- Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndromeAnnals of Oncology, 2007
- Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinomaNature Clinical Practice Nephrology, 2007
- Thrombotic microangiopathy and anti-VEGF agentsNephrology Dialysis Transplantation, 2007
- Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinomaThe Lancet Oncology, 2007
- Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-AnalysisAmerican Journal of Kidney Diseases, 2007
- The role of vascular endothelial growth factor (VEGF) in renal pathophysiologyKidney International, 2004
- Chronic Thrombotic Microangiopathy Associated With Antineoplastic Therapy With Minimal Hematologic EffectsMayo Clinic Proceedings, 2002